Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
Retrieved on:
Wednesday, January 17, 2024
Death, Commissioner, Woman, Placenta, Patient, Intensive care medicine, Pre-eclampsia, Incidence, GV, Health, LAV, Series, Seizure, Nobel, Survivor, Stroke, New Enterprise Associates, Atlas, Small RNA, Medicine, Infant, Atlas Venture, Place of birth, Risk, Food, Pregnancy, Disease, Safety, FDA, Therapy, Capital, GV (company), Venture round, Eli Lilly and Company, Population health, NEA, Diagnosis, Trial of the century, Physician, Growth, Dietary supplement
Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.
Key Points:
- Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.
- It can lead to serious complications for both the mother and the baby, including multi-organ damage, seizures, and premature birth.
- Currently, delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia.
- Scott Johnson, M.D., Chief Executive Officer at Comanche Biopharma, commented, “We are thrilled to have the support and validation of this top-tier investor syndicate.